Gold prices touch four-month high amid Fed easing hopes, softer U.S. dollar
Erin Moore, the Interim Principal Financial (NASDAQ:PFG) Officer and Principal Accounting Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), has recently executed a series of stock transactions. The company, currently valued at $3.16 billion, has seen its stock surge nearly 287% over the past six months, though InvestingPro analysis suggests the shares are trading slightly above their Fair Value. On March 24, Moore sold 13,564 shares of common stock at an average price of $33.12, totaling approximately $449,236.
In addition to the sale, Moore also exercised stock options to acquire a total of 13,564 shares at prices ranging from $13.52 to $23.86, amounting to a total acquisition cost of $235,085. Following these transactions, Moore holds 82,609 shares directly. These transactions were made under a pre-established Rule 10b5-1 trading plan.
In other recent news, Scholar Rock reported a significant earnings miss for Q4 2024, with earnings per share (EPS) at -$2.47, falling short of the forecasted -$0.58. Despite this, the company is preparing for a potential commercial launch of its SMA treatment, apitegromab, in the U.S. by Q4 2025, followed by a European launch in 2026. The U.S. Food and Drug Administration (FDA) has granted a priority review for apitegromab’s Biologics License Application, with a decision expected by September 2025. The European Medicines Agency (EMA) is also reviewing the Marketing Authorization Application for the same treatment.
Analyst firm Truist Securities has reiterated a Buy rating for Scholar Rock, with a target price of $45.00, supported by the FDA’s priority review and EMA’s acceptance of the application. Scholar Rock has also issued inducement equity awards to new employees, consisting of stock options and restricted stock units, under its 2022 Inducement Equity Plan. The company is also advancing its pipeline with plans to file an Investigational New Drug application for SRK-439, targeting cardiometabolic conditions, in the third quarter of 2025. These developments highlight Scholar Rock’s strategic focus on product innovation and market expansion, positioning it for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.